Can-Fite Secures Canadian Patent for Namodenoson Obesity Therapy, Citing 2.3% Weight Loss
Can-Fite received allowance for a Canadian patent covering Namodenoson’s anti-obesity use, building on US and Australian patents. Preclinical studies showed increased adiponectin and reduced body weight in obese animal models, and a Phase IIa MASH trial reported a 2.3% weight loss after three months.
1. Canadian Patent Allowance
Can-Fite has received a notice of allowance for Canadian Patent Application No. 3,126,002, securing intellectual property protection for Namodenoson’s use as an anti-obesity therapy. This adds to existing obesity and metabolic disorder patents in the United States and Australia and extends the company’s A3AR agonist platform into metabolic indications.
2. Clinical Evidence Supporting Patent
The patent application is supported by preclinical data showing Namodenoson increased adiponectin levels and reduced fat mass in high-fat diet animal models. In a Phase IIa study for MASH, patients treated with Namodenoson experienced an average 2.3% body weight reduction after three months alongside elevated serum adiponectin.
3. Market Implications and Pipeline Expansion
By expanding its patent estate to include obesity indications in Canada, Can-Fite positions Namodenoson to tap into the projected $60.5 billion obesity treatment market by 2030. The stronger IP footprint may enable new development partnerships and reinforces the value of Can-Fite’s A3AR platform across oncology, liver, and metabolic diseases.